

August 26, 2013

Europe | Germany | Technology

Update

BUY

Target price: €26.10

Overview

Industry:	Technology
Country:	Germany
ISIN:	DE000A1K0300
Reuters:	EUCAn.DE
Bloomberg:	EUCA GR
Website:	www.euromicron.net

Last price	15.76
	High Low
Price 52 weeks:	22.35 13.63
Market cap (EURm)	105.05
Number of shares (m)	6.66

Shareholder structure

Allianz Global Investors	2.95%
Universal-Investment GmbH	4.92%
Free float	92.13%


Performance

4 weeks	2.21%
13 weeks	-19.84%
26 weeks	-13.62%
52 weeks	-24.15%
YTD	-16.87%

Dividend

	in EUR	in %
2009	1.00	6.34%
2010	1.10	6.98%
2011	1.15	7.30%
2012	0.30	1.90%

52-Week Chart



Analyst

Dr. Norbert Kalliwoda
Email: nk@kalliwoda.com
Phone: +49 69 97 20 58 53
www.kalliwoda.com

euromicron AG

H1/13 in-line with our expectations

- According to euromicron's H1/13 report, revenues went up from €152.8m in H1/12 to €153.1m, which equaled an increase of 0.2% y-o-y. However, due to a significantly lower change of inventories the EBIT margin declined from 6.3% to 6.0% and net income dropped from €5.4m to €5.0m (-7.3% y-o-y). Positive was the development of order intake and backlog, which increased by 4.6% to EUR 154.8m and 3.5% to EUR 127m respectively.
- In H1/13, the best-performing segment was euromicron WAN services, where sales increased by an impressive 15.1% y-o-y to €42.4m. euromicron Nord was up by 5.7% to €56.1m, while revenues of euromicron Sud decreased by 10.6% to €63.1m, though it still remained the largest segment. The most profitable business area was euromicron Nord, with an EBIT margin of 13.8%.
- Despite a lower net income y-o-y, the 6-months operating cash flow improved from €-23.6m in H1/12 to €6.0m. The reasons were lower investments into working capital and higher other operating liabilities. Together with a cash flow from investing of €-5.5m (H1/12: €-4.5m) and financing of €1.5m (H1/12: €24.6m), euromicron's total cash position increased from €2.1m y-o-y to €7.5m. As of 31 March 2013, the company had an equity ratio of 42.7%.
- In the H1/13 report, euromicron's management provided a revenue guidance for 2013 of €350-365m, which is in-line with our current estimate of €358.1m. However, while the company plans to achieve c. €500m by 2015, we are more cautious and expect €426.7m due to low visibility regarding the development of the telecommunication sector in Europe. As we have not adjusted our 2013 EBIT and net income estimates due to the fact that euromicron's H1/13 figures were in-line with our estimates, our 12-months DCF-based price target of €26.10 remains unchanged.

Key Figures

EURm	2009	2010	2011	2012	2013E	2014E
Net sales	187.33	203.64	305.31	330.03	358.08	391.38
EBITDA	21.10	24.73	30.78	25.03	28.18	31.53
EBIT	18.04	20.13	24.22	17.08	19.56	22.11
Net income	10.74	11.46	12.23	8.57	9.44	11.27
EPS	2.39	2.38	2.33	1.29	1.42	1.69
BVPS	17.58	18.45	22.78	17.79	18.49	19.34
RoE	14.16%	13.66%	11.74%	7.20%	7.81%	8.94%
EBIT margin	9.63%	9.88%	7.93%	5.18%	5.46%	5.65%
P/E	6.95x	6.97x	7.12x	12.91x	11.71x	9.81x
P/BVPS	0.94x	0.90x	0.73x	0.93x	0.90x	0.86x
EV/EBITDA	9.41x	8.03x	6.45x	7.93x	7.05x	6.30x

Content

1	Company profile	3
2	Valuation	4
3	H1/13 results	5
4	Outlook	8
5	Stock and shareholder structure	8
6	Profit and loss statements	9
7	Balance sheets	10
8	Cash flow statements	11
9	Financial ratios	11

1 Company profile

euromicron AG is a manufacturer and provider of network solutions and optical fibre technology. Moreover, the company is a full-service provider of communication and security solutions for different industries and requirements. euromicron covers the entire value chain. Along with planning, implementation and maintenance of communication and security solutions, which are usually based on IP networks, the company also offers development, production and distribution of network components as well as consulting and purchasing. The organization is divided into three segments and four marketing areas.

euromicron AG – Company structure

Holding	Management Holding		
	Finance, Personnel, Purchasing, IT, Public & Investor Relations		
	North	South	WAN services
Components	Highest quality in manufacturing, which is conducted according to customer requirements		
	<ul style="list-style-type: none"> Active / Passive Optical Network Components Test and Working Station Systems 		<ul style="list-style-type: none"> Maintenance Managed Services
	LWL Sachsenkabel GmbH (D) MICROSENS GmbH Co. KG & Beteiligungen GmbH (D, F, PL)	ELABO GmbH (D) EUROMICRON Werkzeuge GmbH (D)	
Networks	Integrated, one-stop approach for client-specific, cross-system project and system solutions for convergent networks		
	<ul style="list-style-type: none"> Voice/Unified Communication Video/Monitoring Intelligent Networks 		<ul style="list-style-type: none"> Security PMR Solutions
	euromicron systems GmbH (D) SSM euromicron GmbH (D)	euromicron solutions GmbH (D, P) Avalan GmbH (D) euromicron austria GmbH (A) euromicron NBG Fiber Optics (A)	
Distribution	Long-term relationships with international manufacturers of active and passive network components allow for qualified and independent solutions at best-possible terms just-in-time		
	<ul style="list-style-type: none"> Consulting Training (Certificates, Seminars) 		<ul style="list-style-type: none"> Analysis Service
	SKM Skyline GmbH (D) Qubix S.p.A. networking solutions & distribuion GmbH (I)		
Service	Strategic and cross-segment control and operating tasks, which do not directly belong to the core business e.g.		
	<ul style="list-style-type: none"> Administration of Property and Buildings 		<ul style="list-style-type: none"> Financing of Specific Shareholdings
	euromicron international services GmbH (D)		

2 Valuation

In order to value euromicron, we have used our DCF model, which derives a 12-months price target for the stock of €26.10. Compared to the current market level, this corresponds to an upside of 58%.

DCF model

Discounted Cash Flow Model (Basis 08/2013)

in EURm	Phase 1								
	2013E	2014E	2015E	2016E	2017E	2018E	2019E	2020E	2021E
Net sales	358.08	391.38	426.61	445.81	463.64	478.47	491.39	503.68	514.76
(y-o-y change)	8.5%	9.3%	9.0%	4.5%	4.0%	3.2%	2.7%	2.5%	2.2%
EBIT	19.56	22.11	27.53	32.34	37.35	39.73	40.38	41.22	41.60
(EBIT margin)	5.4%	5.6%	6.4%	7.2%	8.0%	8.3%	8.2%	8.1%	8.0%
NOPLAT	13.69	15.48	19.27	22.64	26.15	27.81	28.27	28.85	29.12
+ Depreciation	8.62	9.42	10.27	10.73	11.16	11.52	11.83	12.12	12.39
= Net operating cash flow	22.31	24.90	29.54	33.37	37.31	39.32	40.10	40.97	41.51
- Total investments (Capex and WC)	-21.96	-24.22	-24.62	-21.95	-22.20	-22.02	-22.00	-22.23	-22.29
Capital expenditure	-15.62	-16.42	-16.27	-16.73	-17.16	-17.52	-17.83	-18.12	-18.39
Working capital	-6.35	-7.80	-8.35	-5.22	-5.04	-4.51	-4.17	-4.11	-3.90
= Free cash flow (FCF)	0.35	0.67	4.91	11.42	15.10	17.30	18.10	18.74	19.22
PV of FCFs	0.34	0.60	4.06	8.72	10.66	11.28	10.90	10.43	9.87
PV of FCFs in explicit period	76.14								
PV of FCFs in terminal period	172.79								
Enterprise value (EV)	248.93								
+ Net cash / - net debt	-87.91								
+ Investments / - Minorities	-0.37								
Shareholder value	160.66								
Number of shares outstanding (m)	6.66								
WACC	8.3%								
Equity costs	9.7%								
Debt costs before tax	7.0%								
Tax rate	30.0%								
Debt costs after tax	4.9%								
Equity share	70.0%								
Debt share	30.0%								
Fair value per share in € (today)	24.11								
Fair value per share in € (in 12 months)	26.10								

Sensitivity analysis		Terminal EBIT margin						
		4.9%	5.9%	6.9%	7.9%	8.9%	9.9%	10.9%
WACC	5.3%	35.91	47.46	59.00	70.55	82.09	93.64	105.18
	6.3%	24.42	32.50	40.59	48.67	56.76	64.84	72.93
	7.3%	17.21	23.21	29.21	35.20	41.20	47.19	53.19
	8.3%	12.25	16.86	21.48	26.10	30.72	35.34	39.95
	9.3%	8.60	12.25	15.91	19.56	23.21	26.86	30.52
	10.3%	5.80	8.75	11.70	14.65	17.59	20.54	23.49

Source: Dr. Kalliwoda Research GmbH

Peer Group Analysis

We have additionally conducted a plausibility check of the valuation, which was derived by our DCF model. The application of a relative valuation method is based on the idea that comparable companies have similar market values. Hence, mainly listed companies are chosen, which offer similar products, or have a comparable business model. An analysis of financial figures provides an estimation to which degree the company's valuation stems from a low comparability with its peer group or an under- or overvaluation.

The input data of the peers stem from the information provider Thomson Reuters. The forward-looking financial data of the peer group represent the mean average of all analyst estimates, which are available on ThomsonReutersKnowledge. We have used the book value in order to approximate the market value of financial liabilities.

Peers	Enterprise Value Multiples						Equity Value Multiples			
	EV / Sales		EV / EBITDA		EV / EBIT		Price / Eps		Price / Bvps	
	FY2013	FY2014	FY2013	FY2014	FY2013	FY2014	FY2013	FY2014	FY2013	FY2014
ADVA Optical Networking SE	0.6	0.6	4.5	5.4	15.5	11.5	21.5	15.7	1.2	1.1
Alliance Fiber Optic Products Inc	3.4	3.0	28.2	12.8	14.2	12.4	18.1	16.5	4.2	3.8
Batenburg Techniek NV	0.3	0.3	7.4	12.7	14.8	13.9	n.a.	12.6	0.8	0.8
Huber & Suhner AG	1.1	1.0	13.0	9.6	15.6	12.8	19.4	16.1	1.4	1.3
Royal Imtech NV	0.5	0.5	9.1	24.2	30.7	17.1	n.a.	5.6	0.6	0.4
euromicron AG	0.5	0.5	6.8	6.1	9.9	8.7	11.1	9.3	0.9	0.8
Median	0.5	0.5	9.1	12.7	15.2	12.8	18.7	15.7	0.9	0.8
Mean	1.0	0.9	12.8	12.3	16.8	14.0	17.5	14.7	1.4	1.3
Peer Benchmark	0.5	0.5	9.1	12.7	15.2	12.8	18.7	15.7	0.9	0.8
Discount (-)/Premium (+)	0%	-7%	-25%	-52%	-35%	-32%	-41%	-41%	0%	0%

Valuation										
Peer Benchmark	0.5	0.5	9.1	12.7	15.2	12.8	18.7	15.7	0.9	0.8
euromicron AG financials	358.1	391.4	28.2	31.5	19.6	22.1	1.4	1.7	18.5	19.3
Implied Enterprise Value	192.9	206.6	256.5	400.8	296.9	283.9				
+ Cash and Cash Equivalents	7.5	7.5	7.5	7.5	7.5	7.5				
- Financial Debt	95.4	95.4	95.4	95.4	95.4	95.4				
- Pension Liabilities	0.0	0.0	0.0	0.0	0.0	0.0				
- Minority Interest	0.0	0.0	0.0	0.0	0.0	0.0				
- Preferred Equity	0.0	0.0	0.0	0.0	0.0	0.0				
+ Change in Equity Capital	0.0	0.0	0.0	0.0	0.0	0.0				
Implied Equity Value	105.0	118.7	168.6	312.9	209.0	196.0				
Number of Shares	6.7	6.7	6.7	6.7	6.7	6.7				
Implied fair value per share	15.8	17.8	25.3	47.0	31.4	29.4	26.6	26.6	15.8	15.8
Weights	17%	17%	17%	17%	17%	17%	25%	25%	25%	25%
Results	27.78						21.17			
Weights	10%	10%	10%	10%	10%	10%	10%	10%	10%	10%
Fair Value Implied by Both Peer Multiples:						25.14 EUR				
Premium (Discount) to Peer Benchmark: 0 %										
Fair Value per Share 25.14 EUR										

Source: Dr. Kalliwoda | Research 2013

Based on our peer group multiples, the implied fair value equals EUR 25.14 per share.

3 H1/13 results

Revenues

In H1/13, euromicron generated total revenues of €153.1m, which were 0.2% higher y-o-y. 89.6% of sales stemmed from Germany, while Rest of EU and Rest of the World accounted for 8.6% and 1.8% respectively. Order intake and backlog amounted to €154.8m (+4.6% y-o-y) and €127m (+3.5% y-o-y) respectively.

In H1/13, the best-performing segment was again euromicron WAN services, where sales increased by 15.1% y-o-y to €42.4m. euromicron Nord was up by 57% to €56.1m and also generated the highest EBIT margin of 13.8%. Revenues of euromicron Sud, the largest segment, advanced by 10.6% to €63.1m.

H1/13 results vs. previous year

H1/13 vs. previous year			
in EURm	H1/13	H1/12	change (%)
Net sales	153.09	152.80	0.2%
EBITDA	13.42	13.68	-1.9%
EBITDA margin	8.8%	9.0%	
EBIT	9.22	9.66	-4.6%
EBIT margin	6.0%	6.3%	
Net income	5.04	5.44	-7.3%
Net margin	3.3%	3.6%	

Source: Company data, Dr. Kalliwoda Research GmbH


Sales and EBIT margins according to segments

Sales and EBIT margins according to segments H1/13 vs. H1/12					
	H1/13	H1/12		H1/13	H1/12
euromicron Nord			euromicron WAN services		
Sales €m	56.05	53.03	Sales €m	42.36	36.81
share in total sales	36.6%	34.7%	share in total sales	27.7%	24.1%
EBIT margin	13.8%	15.1%	EBIT margin	5.6%	2.9%
euromicron Süd			Group (after consolidation)		
Sales €m	63.08	70.54	Total sales	153.09	152.80
share in total sales	41.2%	46.2%	change y-o-y	0.2%	
EBIT margin	3.1%	4.8%			
Germany			Rest of the World		
Sales €m	137.13	135.58	Sales €m	2.73	2.26
share in total sales	89.6%	88.7%	share in total sales	1.8%	1.5%
Euro zone					
Sales €m	13.23	14.96			
share in total sales	8.6%	9.8%			

Source: Company data, Dr. Kalliwoda Research GmbH

Profitability

Share in total revenues H1/13 vs. H1/12



Source: Company information, Dr. Kalliwoda Research GmbH

In H1/13, EBIT and net income developed weaker y-o-y. Operating profit went down by 4.6% y-o-y to €9.2m and net income by 7.3% to €5.0m, which mainly stemmed from a lower change of inventories. However, in general euromicron made good progress in terms of optimizing its cost structures.

Balance Sheet and Cash Flow

At the end of June 2013, the largest positions on euromicron's balance sheet were (1) Equity of €121.6m (2) goodwill of €106.4m and (3) accounts receivables of €68.3m. As of 30 June 2013, long-term interest-bearing debt amounted to €54.3m, while short-term liabilities equalled €41.1m. With cash and equivalents of €7.5m, net debt amounted to €87m (H1/12: €79.5m and net gearing to 72.3% (67.1%).


Despite a lower net income y-o-y, the 6-months operating cash flow improved from €-23.6m in to €6.0m. The reasons were lower investments into working capital (€11.7m vs. €22m in H1/12) and higher other operating liabilities (€5m vs. €-8.7m). Together with a cash flow from investing of €-5.5m (H1/12: €-4.5m) and financing of €1.5m (H1/12: €2.4m), euromicron's total cash position increased from €5.4m at the beginning of January to €7.5m. As of 31 June 2013, the company had an equity ratio of 42.7%.

4 Outlook

After H1/13 results, which were in-line with our expectations, we have kept our estimates and our 12-months price target of €26.10 unchanged. Our forecasts are at the lower end of euromicron's guidance, which predicts an organic sales growth of 5%-10% in 2013 and 2014 and revenues of €500m in 2015, among others by a much stronger investment activity in the Telco sector. As management plan to reduce expenses by €10m, EBITDA margin in 2013 and 2014 is forecast at 8-11%.


5 Stock and shareholder structure

Share performance



Source: Thomsosn Reuters Knowledge, Dr. Kalliwoda Research GmbH

Shareholder structure



Source: Company information, Dr.Kalliwoda Research GmbH

6 Profit and loss statements

Profit and loss statement - euromicron AG						
in EURm	Fiscal year					
	2009	2010	2011	2012	2013E	2014E
Sales split						
<i>euromicron Nord</i>	92.53	103.66	116.79	111.65	120.78	131.62
<i>euromicron Süd</i>	102.48	108.99	137.63	131.52	142.35	155.19
<i>WAN Services</i>	0.00	0.00	66.85	102.84	112.86	124.14
<i>Consolidation</i>	-7.68	-9.01	-15.96	-15.98	-17.90	-19.57
Net sales	187.33	203.64	305.31	330.03	358.08	391.38
<i>Internally produced and capitalised assets</i>	1.70	1.52	1.95	5.61	1.90	1.90
<i>Change in inventories</i>	-6.88	1.21	-7.44	-5.85	2.28	1.53
Total Output	182.15	206.38	299.81	329.79	362.26	394.82
<i>Cost of goods sold</i>	-92.47	-107.32	-159.62	-171.00	-187.84	-204.72
Gross profit	89.69	99.06	140.19	158.79	174.42	190.10
<i>Other operating income</i>	2.10	4.48	2.72	2.80	7.25	7.90
<i>Personnel costs</i>	-48.14	-54.25	-76.88	-93.59	-102.08	-110.46
<i>Depreciation & Amortization</i>	-3.06	-4.60	-6.56	-7.94	-8.62	-9.42
<i>Other operating expenses</i>	-22.55	-24.56	-35.26	-42.97	-51.41	-56.00
EBIT	18.04	20.13	24.22	17.08	19.56	22.11
<i>Net financial results</i>	-2.83	-2.91	-6.36	-4.86	-5.65	-5.50
EBT	15.21	17.22	17.85	12.23	13.91	16.61
<i>Income taxes</i>	-3.76	-5.09	-4.95	-3.40	-4.17	-4.98
<i>Minority interests</i>	-0.70	-0.67	-0.67	-0.26	-0.30	-0.35
Net income / loss	10.74	11.46	12.23	8.57	9.44	11.27
<i>EPS</i>	2.39	2.38	2.33	1.29	1.42	1.69
<i>DPS</i>	0.96	1.06	1.15	0.40	1.15	1.18
Change y-o-y						
<i>Net sales</i>	n.a	8.71%	49.92%	8.10%	8.50%	9.30%
<i>Total Output</i>	n.a	13.30%	45.27%	10.00%	9.85%	8.99%
<i>Cost of goods sold</i>	n.a	16.06%	48.74%	7.13%	9.85%	8.99%
<i>Gross profit</i>	n.a	10.45%	41.53%	13.26%	9.85%	8.99%
<i>Other operating income</i>	n.a	113.04%	-39.14%	2.68%	159.03%	8.99%
<i>Personnel costs</i>	n.a	12.70%	41.71%	21.74%	9.07%	8.21%
<i>Depreciation & Amortization</i>	n.a	50.36%	42.64%	21.03%	8.50%	9.30%
<i>Other operating expenses</i>	n.a	8.90%	43.57%	21.86%	19.64%	8.93%
<i>EBIT</i>	n.a	11.58%	20.33%	-29.46%	14.52%	13.02%
<i>Net financial results</i>	n.a	2.61%	119.00%	-23.70%	16.35%	-2.65%
<i>EBT</i>	n.a	13.25%	3.68%	-31.51%	13.79%	19.39%
<i>Income taxes</i>	n.a	35.39%	-2.65%	-31.40%	22.83%	19.39%
<i>Net income / loss</i>	n.a	6.68%	6.69%	-29.94%	10.21%	19.39%
<i>EPS</i>	n.a	-0.42%	-2.10%	-44.82%	10.21%	19.39%
<i>DPS</i>	n.a	9.99%	8.80%	-65.22%	187.50%	2.61%
Share in total sales						
<i>Net sales</i>	100.00 %	100.00 %	100.00 %	100.00 %	100.00 %	100.00 %
<i>Total Output</i>	59.66 %	67.60 %	98.20 %	108.02 %	118.65 %	129.32 %
<i>Cost of goods sold</i>	-30.29 %	-35.15 %	-52.28 %	-51.81 %	-52.46 %	-52.31 %
<i>Gross profit</i>	29.38 %	32.45 %	45.92 %	48.11 %	48.71 %	48.57 %
<i>Other operating income</i>	0.69 %	1.47 %	0.89 %	0.85 %	2.02 %	2.02 %
<i>Personnel costs</i>	-15.77 %	-17.77 %	-25.18 %	-28.36 %	-28.51 %	-28.22 %
<i>Depreciation & Amortization</i>	-1.00 %	-1.51 %	-2.15 %	-2.41 %	-2.41 %	-2.41 %
<i>Other operating expenses</i>	-7.39 %	-8.04 %	-11.55 %	-13.02 %	-14.36 %	-14.31 %
<i>EBIT</i>	5.91 %	6.59 %	7.93 %	5.18 %	5.46 %	5.65 %
<i>Net financial results</i>	-0.93 %	-0.95 %	-2.08 %	-1.47 %	-1.58 %	-1.41 %
<i>EBT</i>	4.98 %	5.64 %	5.85 %	3.70 %	3.89 %	4.24 %
<i>Income taxes</i>	-1.23 %	-1.67 %	-1.62 %	-1.03 %	-1.17 %	-1.27 %
<i>Net income / loss</i>	3.52 %	3.75 %	4.01 %	2.60 %	2.64 %	2.88 %

Dr. Kalliwoda | Research © 2013

7 Balance sheets

Balance sheet - euromicron AG						
in EURm	Fiscal year					
	2009	2010	2011	2012	2013E	2014E
Assets						
Cash and cash equivalents	9.77	8.57	7.30	5.41	0.58	0.82
Inventories	13.24	17.19	25.08	27.50	30.21	32.92
Trade accounts and notes receivables	51.20	54.72	88.07	96.77	104.99	114.76
Other current assets	4.49	4.81	5.17	7.47	8.10	8.86
Other financial assets	0.00	1.33	1.16	0.23	0.25	0.27
Current assets	78.69	86.63	126.78	137.38	144.12	157.62
Property, plant and equipment	10.91	11.56	15.13	16.26	18.76	21.26
Other intangible assets	9.58	14.81	18.26	21.03	25.53	30.03
Goodwill	84.04	81.88	103.63	106.37	106.37	106.37
Financial assets	1.08	0.89	0.73	0.72	0.78	0.85
Other assets	0.19	0.10	0.18	0.20	0.21	0.23
Deferred tax assets	1.41	0.37	0.47	1.93	0.00	0.00
Non-current assets	107.21	109.60	138.39	146.50	151.65	158.74
Total assets	185.91	196.23	265.16	283.88	295.77	316.36
Liabilities						
Trade payables	20.52	22.37	31.62	42.87	46.06	49.08
Tax liabilities	2.61	4.71	9.70	7.98	8.66	9.46
Personnel liabilities	1.11	3.86	9.67	9.83	10.67	11.66
Other short-term liabilities	4.93	2.47	13.88	6.07	6.59	7.20
Short-term bank debt	49.81	45.29	29.76	31.00	30.00	29.00
Finance lease	0.20	0.19	0.30	0.60	0.64	0.68
Other financial liabilities	0.00	2.53	2.97	6.78	6.58	6.38
Provisions	1.47	0.07	1.22	2.06	2.24	2.45
Current liabilities	80.64	81.48	99.12	107.19	111.42	115.90
Long-term bank debt	8.16	4.40	24.67	37.59	42.59	55.59
Leasing debt	0.54	0.82	1.46	2.16	2.41	2.66
Other financial debt	10.00	10.77	10.79	8.03	8.07	8.11
Pension provisions	0.00	0.66	0.73	0.98	1.07	1.17
Provisions	1.01	0.14	0.48	1.16	1.26	1.37
Other liabilities	0.10	2.08	0.00	0.00	0.00	0.00
Deferred tax liabilities	5.19	6.62	7.87	7.74	4.90	1.52
Long-term liabilities	25.00	25.49	46.00	57.65	60.29	70.41
Total liabilities	105.64	106.97	145.12	164.83	171.71	186.31
Shareholders equity	79.02	88.83	119.56	118.52	123.24	128.88
Minority interests	1.25	0.43	0.48	0.53	0.82	1.17
Total equity and liabilities	185.91	196.23	265.16	283.88	295.77	316.36

Dr. Kalliwoda | Research © 2013

8 Cash flow statements


Cash flow statement - euromicron AG						
in EURm	Fiscal year					
	2009	2010	2011	2012	2013E	2014E
Net income / loss	10.74	11.46	12.23	8.57	9.44	11.27
Depreciation & Amortization	3.06	4.60	6.56	7.94	8.62	9.42
Change of working capital	3.34	-10.91	-25.36	-11.82	-6.35	-7.80
Others	-2.92	3.33	7.04	-0.08	-0.63	-3.06
Net operating cash flow	14.23	8.48	0.47	6.96	11.09	9.83
Cash flow from investment	-9.87	-5.98	-20.40	-13.29	-15.62	-16.42
Free cash flow	4.35	2.50	-19.92	-6.33	-4.53	-6.59
Cash flow from financing	-5.89	-2.56	18.65	4.45	-0.31	6.83
Change of cash	-1.54	-0.06	-1.27	-1.89	-4.84	0.24
Cash at the beginning of the period	10.17	8.63	8.57	7.30	5.41	0.58
Cash at the end of the period	8.63	8.57	7.30	5.41	0.58	0.82

Dr. Kalliwoda | Research © 2013








9 Financial ratios

Fiscal year	2009	2010	2011	2012E	2013E	2014E	2015E	2016E
Gross margin	49.24%	48.00%	46.76%	48.15%	48.15%	48.15%	48.15%	48.15%
EBITDA margin	11.26%	12.14%	10.08%	7.58%	7.87%	8.06%	8.86%	9.66%
EBIT margin	9.90%	9.75%	8.08%	5.50%	5.40%	5.60%	6.40%	7.20%
Net margin	5.90%	5.55%	4.08%	2.60%	2.61%	2.86%	3.49%	4.08%
Return on equity (ROE)	14.16%	13.66%	11.74%	7.20%	7.81%	8.94%	11.32%	13.00%
Return on assets (ROA)	7.58%	7.52%	8.06%	4.89%	5.21%	5.48%	6.26%	6.90%
Return on capital employed (ROCE)	12.90%	12.36%	10.54%	6.98%	7.43%	7.72%	8.94%	9.94%
Net debt (in EURm)	58.94	54.76	62.22	81.49	90.52	102.48	110.14	111.49
Net gearing	74.59%	61.64%	52.04%	68.75%	73.45%	79.52%	80.75%	76.60%
Equity ratio	42.50%	45.27%	45.09%	41.75%	41.67%	40.74%	40.55%	41.60%
Current ratio	0.98	1.06	1.28	1.28	1.29	1.36	1.42	1.47
Quick ratio	0.76	0.79	0.97	0.96	0.95	1.00	1.04	1.08
Net interest cover	6.37	6.93	3.81	3.52	3.46	4.02	5.10	6.05
Net debt/EBITDA	2.79	2.21	2.02	3.26	3.21	3.25	2.91	2.59
Tangible BVPS	-1.12	1.44	3.04	1.82	2.53	3.38	4.50	5.88
Capex/Sales	-6.69%	-4.08%	-11.57%	-4.42%	-4.36%	-4.20%	-3.81%	-3.75%
Working capital/Sales	21.23%	21.27%	17.51%	19.69%	19.92%	20.22%	20.51%	20.80%
EV/Sales	1.06	0.97	0.65	0.60	0.55	0.51	0.47	0.45
EV/EBITDA	9.41	8.03	6.45	7.93	7.05	6.30	5.25	4.61
EV/EBIT	11.01	9.86	8.20	11.62	10.15	8.98	7.21	6.14
P/Tangible BVPS	-14.84	11.49	5.47	9.10	6.56	4.91	3.69	2.82
P/E	6.95	6.97	7.12	12.91	11.71	9.81	7.37	6.04
P/FCF	31.99	-4.01	-12.63	-17.65	-12.13	-155.24	10.97	7.34

Source: Company information, Dr. Kalliwoda Research GmbH



Sales split 2012



Source: Company information, Dr. Kalliwoda Research GmbH

DR. KALLIWODA RESEARCH GmbH		Arndtstr. 47 60325 Frankfurt Tel.: 069-97 20 58 53 Fax: 069-13 81 92 15 www.kalliwoda.com
Primary Research Fair Value Analysis International Roadshows		
Head: Dr. Norbert Kalliwoda E-Mail: nk@kalliwoda.com	CEFA-Analyst; University of Frankfurt/Main; PhD in Economics; Dipl.-Kfm.	<u>Sectors:</u> IT, Software, Electricals & Electronics, Mechanical Engineering, Logistics, Laser, Technology, Raw Materials
Dr. Peter Arendarski E-Mail: pa@kalliwoda.com	Senior-Analyst, Msc & Ph.D in Finance (Poznan Univers. of Economics), CFA Level 3 Candidate	<u>Sectors:</u> Technology, Raw Materials, Banks & Insurances, Financial-Modelling (Quant., Buyside)
Patrick Bellmann E-Mail: pb@kalliwoda.com	Junior-Analyst; WHU - Otto Beisheim School of Management, Vallendar	<u>Sectors:</u> Support Research and Quantitative Approach
Andreas Braun E-Mail: rb@kalliwoda.com	Junior-Analyst; University of Frankfurt/Main	<u>Sectors:</u> Support Research and Quantitative Approach
Michael John E-Mail: mj@kalliwoda.com	Dipl.-Ing. (Aachen)	<u>Sectors:</u> Chemicals, Chemical Engineering, Basic Metals, Renewable Energies, Laser/Physics
Rainer Koch E-Mail: rk@kalliwoda.com	Computer-Science/Dipl.-Betriebw, (Frankfurt); seasoned international Executive IT-Industry	<u>Sectors:</u> IT, IT-Services, Internet, Media, Internet, Emerging Markets
Adrian Kowolik E-Mail: ak@kalliwoda.com	Dipl.-Kfm.; Humboldt-Universität zu Berlin, CFA Candidate	<u>Sectors:</u> Media, Internet, Gaming, Technology, Eastern European stocks
Maximilian F. Kaessens E-Mail: mk@kalliwoda.com	Bachelor of Science in Business Administration (Babson College, Babson Park, MA (US))	<u>Sectors:</u> Financials, Real Estate
Dr. Christoph Piechaczek E-Mail: cp@kalliwoda.com	Dipl.-Biologist; Technical University Darmstadt; Univ. Witten-Herdecke.	<u>Sectors:</u> Biotech & Healthcare; Medical Technology Pharmaceutical
Dario Maugeri E-Mail: dm@kalliwoda.com	Master of Science in Corporate Finance; Rotterdam School of Management norb	<u>Sectors:</u> Automotive, Technology
Hellmut Schaarschmidt; E-Mail: hs@kalliwoda.com	Dipl.-Geophysicists; University of Frankfurt/Main.	<u>Sectors:</u> Oil, Regenerative Energies, Specialities Chemicals, Utilities
Dr. Erik Schneider E-Mail: es@kalliwoda.com	Dipl.-Biologist; Technical University Darmstadt; Univ. Hamburg.	<u>Sectors:</u> Biotech & Healthcare; Medical Technology Pharmaceutical
David Schreindorfer E-Mail: ds@kalliwoda.com	MBA, Economic Investment Management; Univ. Frankfurt/ Univ. Iowa (US).	<u>Sectors:</u> IT/Logistics; Quantitative Modelling
Rainer Wochele E-Mail: rw@kalliwoda.com	Bachelor of Science in Economics and Business Administration (Goethe University Frankfurt M. / Graduation Fall 2013)	<u>Junior-Analyst</u>
Nele Rave E-Mail: nr@kalliwoda.com	Lawyer; Native Speaker, German School London,	<u>Legal adviser</u>

Also view Sales and Earnings Estimates:

DR. KALLIWODA | RESEARCH on Terminals of Bloomberg, Thomson Reuters, vwd group and Factset

Analyst of this research:
Dr. Norbert Kalliwoda,
CEFA



KAUFEN:	Die Aktie wird auf Basis unserer Prognosen auf Sicht von 12 Monaten eine Kursentwicklung von mindestens 10 % aufweisen	BUY
AKKUMULIEREN:	Die Aktie wird auf Basis unserer Prognosen auf Sicht von 12 Monaten eine Kursentwicklung zwischen 5% und 10% aufweisen	ACCUMULATE
HALTEN:	Die Aktie wird auf Basis unserer Prognosen auf Sicht von 12 Monaten eine Kursentwicklung zwischen 5% und - 5% aufweisen	HOLD
REDUZIEREN:	Die Aktie wird auf Basis unserer Prognosen auf Sicht von 12 Monaten eine Kursentwicklung zwischen - 5% und - 10% aufweisen	REDUCE
VERKAUFEN:	Die Aktie wird auf Basis unserer Prognosen auf Sicht von 12 Monaten eine Kursentwicklung von mindestens - 10 % aufweisen	SELL

Additional Disclosure/Erklärung

DR.KALLIWODA | RESEARCH GmbH hat diese Analyse auf der Grundlage von allgemein zugänglichen Quellen, die als zuverlässig gelten, gefertigt. Wir arbeiten so exakt wie möglich. Wir können aber für die Ausgewogenheit, Genauigkeit, Richtigkeit und Vollständigkeit der Informationen und Meinungen keine Gewährleistung übernehmen.

Diese Studie ersetzt nicht die persönliche Beratung. Diese Studie gilt nicht als Aufforderung zum Kauf oder Verkauf der in dieser Studie angesprochenen Anlageinstrumente. Daher rät DR.KALLIWODA | RESEARCH GmbH, sich vor einer Wertpapierdisposition an Ihren Bankberater oder Vermögensverwalter zu wenden.

Diese Studie ist in Großbritannien nur zur Verteilung an Personen bestimmt, die in Art. 11 (3) des Financial Services Act 1986 (Investments Advertisements) (Exemptions) Order 1996 (in der jeweils geltenden Fassung) beschrieben sind. Diese Studie darf weder direkt noch indirekt an einen anderen Kreis von Personen weitergeleitet werden. Die Verteilung dieser Studie in andere internationale Gerichtsbarkeiten kann durch Gesetz beschränkt sein und Personen, in deren Besitz diese Studie gelangt, sollten sich über gegebenenfalls vorhandene Beschränkungen informieren und diese einhalten.

DR.KALLIWODA | RESEARCH GmbH sowie Mitarbeiter können Positionen in irgendwelchen in dieser Studie erwähnten Wertpapieren oder in damit zusammenhängenden Investments halten und können diese Wertpapiere oder damit zusammenhängende Investments jeweils aufstocken oder veräußern.

Mögliche Interessenskonflikte

Weder DR.KALLIWODA | RESEARCH GmbH noch ein mit ihr verbundenes Unternehmen

- a) hält in Wertpapieren, die Gegenstand dieser Studie sind, 1% oder mehr des Grundkapitals;
- b) war an einer Emission von Wertpapieren, die Gegenstand dieser Studie sind, beteiligt;
- c) hält an den Aktien des analysierten Unternehmens eine Netto-Verkaufsposition in Höhe von mindestens 1% des Grundkapitals;
- d) hat die analysierten Wertpapiere auf Grund eines mit dem Emittenten abgeschlossenen Vertrages an der Börse oder am Markt betreut.

Nur mit dem Unternehmen euromicron AG bestehen vertragliche Beziehungen zu DR.KALLIWODA | RESEARCH GmbH für die Erstellung von Research-Studien.

Durch die Annahme dieses Dokumentes akzeptiert der Leser/Empfänger die Verbindlichkeit dieses Disclaimers.

DISCLAIMER

The information and opinions in this analysis were prepared by DR. KALLIWODA | RESEARCH GmbH. The information herein is believed by DR. KALLIWODA | RESEARCH GmbH to be reliable and has been obtained from public sources believed to be reliable. With the exception of information about DR. KALLIWODA | RESEARCH GmbH, DR. KALLIWODA | RESEARCH GmbH makes no representation as to the accuracy or completeness of such information.

Opinions, estimates and projections in this report constitute the current judgement of the author as of the date of this analysis. They do not necessarily reflect the opinions, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, except if research on the subject company is withdrawn. Prices and availability of financial instruments also are subject to change without notice. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction. The financial instruments discussed in this report may not be suitable for all investors and investors must make their own investment decision using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives. If a financial instrument is denominated in a currency other than an investor's currency, a change in exchange rates may adversely affect the price or value of, or the income derived from, the financial instrument, and such investor effectively assumes currency risk. In addition, income from an investment may fluctuate and the price or value of financial instruments described in this report, either directly or indirectly, may rise or fall. Furthermore, past performance is not necessarily indicative of future results.

This report may not be reproduced, distributed or published by any person for any purpose without DR. KALLIWODA | RESEARCH GmbH's prior written consent. Please cite source when quoting.